Literature DB >> 32299852

Short-term and long-term effect of a high-intensity pulmonary rehabilitation programme in obese patients with asthma: a randomised controlled trial.

Yasemin Türk1, Willy Theel2, Astrid van Huisstede3,4, Gert-Jan M van de Geijn5,6, Erwin Birnie6,7, Pieter S Hiemstra8, Jacob K Sont9, Christian Taube8,10, Gert-Jan Braunstahl3,11.   

Abstract

OBJECTIVE: To determine the short-term and long-term effects of a high intensity pulmonary rehabilitation programme on asthma control, body composition, lung function and exercise capacity in obese asthma patients.
METHODS: Patients with obesity (body mass index (BMI)≥30 kg·m-2) and suboptimal controlled asthma (Asthma Control Questionnaire (ACQ)≥0.75) were randomly assigned to a 3-month pulmonary rehabilitation programme (PR only), pulmonary rehabilitation programme with the use of an internet based self-management support programme (PR+SMS) or usual care. The pulmonary rehabilitation programme included high-intensity interval training, nutritional intervention and psychological group sessions. Patients in the usual care group were advised to lose weight and to exercise. The primary outcome was the difference of change of ACQ between PR only and PR+SMS after 3 months. Total follow-up was 12 months.
RESULTS: 34 patients were included in the study (14 PR only, nine PR+SMS, 11 control). Compared with patients in usual care, patients in the PR only group had a significant reduction in BMI and significant improvements in asthma control, exercise capacity and aerobic capacity after 3 months. These improvements persisted during 12 months of follow-up. No difference in ACQ between PR+SMS and PR only groups was observed. However, users of the SMS programme had a significantly lower BMI after 12 months compared with subjects in the PR only group.
CONCLUSION: A high-intensity pulmonary rehabilitation programme provides sustained improvements in asthma control, body composition and exercise capacity in obese asthmatics that are not optimally controlled and, therefore, should be considered in the treatment of these patients.
Copyright ©ERS 2020.

Entities:  

Mesh:

Year:  2020        PMID: 32299852     DOI: 10.1183/13993003.01820-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

Review 1.  Pulmonary rehabilitation versus usual care for adults with asthma.

Authors:  Christian R Osadnik; Ciara Gleeson; Vanessa M McDonald; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2022-08-22

Review 2.  Blended Self-Management Interventions to Reduce Disease Burden in Patients With Chronic Obstructive Pulmonary Disease and Asthma: Systematic Review and Meta-analysis.

Authors:  Xiaoyue Song; Cynthia Hallensleben; Weihong Zhang; Zongliang Jiang; Hongxia Shen; Robbert J J Gobbens; Rianne M J J Van Der Kleij; Niels H Chavannes; Anke Versluis
Journal:  J Med Internet Res       Date:  2021-03-31       Impact factor: 5.428

3.  Recruitment and Retention of Healthy Women with Obesity for a Psychophysiological Study before and After Weight Loss: Insights, Challenges, and Suggestions.

Authors:  Dharini M Bhammar; Vipa Bernhardt; Jonathon L Stickford; Charles Miller; Tony G Babb
Journal:  J Obes Weight Loss Ther       Date:  2021-02-28

4.  A pragmatic randomised controlled trial of tailored pulmonary rehabilitation in participants with difficult-to-control asthma and elevated body mass index.

Authors:  Helen Clare Ricketts; Varun Sharma; Femke Steffensen; Anna Goodfellow; Elaine Mackay; Gordon MacDonald; Duncan S Buchan; Rekha Chaudhuri; Douglas C Cowan
Journal:  BMC Pulm Med       Date:  2022-09-24       Impact factor: 3.320

Review 5.  The Role of Nutritional Factors in Asthma: Challenges and Opportunities for Epidemiological Research.

Authors:  Annabelle Bédard; Zhen Li; Wassila Ait-Hadad; Carlos A Camargo; Bénédicte Leynaert; Christophe Pison; Orianne Dumas; Raphaëlle Varraso
Journal:  Int J Environ Res Public Health       Date:  2021-03-15       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.